87 related articles for article (PubMed ID: 1478615)
1. Identification of müllerian inhibiting substance specific binding in human cell lines.
MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
4. Identification of a receptor for human müllerian inhibiting substance.
Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT
Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody to Mullerian inhibiting substance.
Mudgett-Hunter M; Budzik GP; Sullivan M; Donahoe PK
J Immunol; 1982 Mar; 128(3):1327-33. PubMed ID: 6895760
[TBL] [Abstract][Full Text] [Related]
6. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
8. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
9. Anti-idiotypic antibodies to a monoclonal antibody raised against anti-müllerian hormone exhibit anti-müllerian biological activity.
Lefèvre G; Tran D; Hoebeke J; Josso N
Mol Cell Endocrinol; 1989 Mar; 62(1):125-33. PubMed ID: 2787251
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
11. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
12. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of anti-thyrotropin anti-idiotypic antibody.
Islam MN; Pepper BM; Briones-Urbina R; Farid NR
Eur J Immunol; 1983 Jan; 13(1):57-63. PubMed ID: 6299753
[TBL] [Abstract][Full Text] [Related]
14. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
16. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies.
Greenspan NS; Monafo WJ; Davie JM
J Immunol; 1987 Jan; 138(1):285-92. PubMed ID: 2431057
[TBL] [Abstract][Full Text] [Related]
17. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
18. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
19. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
20. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]